Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$99.98 USD

99.98
61,238

-4.32 (-4.14%)

Updated Aug 2, 2024 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Small-Cap ETFs in Focus on Trade Woes, Solid Economic Data

The small-cap space has been outperforming the large caps this year. Here are the most-popular small-cap ETFs.

    Looking for a Top Momentum Pick? Why Ligand Pharmaceuticals (LGND) is a Great Choice

    Does Ligand Pharmaceuticals (LGND) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Top Ranked Momentum Stocks to Buy for September 7th

      Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 7th:

        bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy

        bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.

          ProQR Up More Than 120% on Favorable Eye Disorder Study Data

          ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

            Top Ranked Momentum Stocks to Buy for September 6th

            Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 6th:

              Horizon Pharma Completes Enrollment in Eye Disease Study

              Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.

                Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout

                Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.

                  Ligand (LGND) Up 4.6% Since Last Earnings Report: Can It Continue?

                  Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?

                    Is (LGND) Outperforming Other Medical Stocks This Year?

                      Top Ranked Momentum Stocks to Buy for September 4th

                      Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 4th

                        Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A

                        Bayer's (BAYRY) Jivi gets FDA approval for the treatment of hemophilia A in previously-treated adults and adolescents aged 12 years and older.

                          Alnylam Gets European Nod for First-Ever RNAi Therapeutic

                          Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.

                            Vertex Inks Deal With Genomics to Make Serious Disease Drugs

                            Vertex (VRTX) signs a three-year collaboration contract with Genomics to develop novel drug targets for advancing discovery of precision medicines.

                              Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data

                              Ultragenyx (RARE) plans to submit an NDA for UX007 for the treatment of LC-FAOD on existing data, as per agreement with the FDA.

                                Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use

                                Amgen's (AMGN) leukemia drug, Blincyto gets approval in EU for use in pediatric patients aged one year or older.

                                  Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval

                                  Ultragenyx's (RARE) Mepsevii gets European approval for the treatment of Mucopolysaccharidosis VII.

                                    Bayer's Blood Thinner Xarelto Fails in Line Extension Studies

                                    Bayer (BAYRY) and partner Johnson & Johnson's drug, Xarelto shows no significant difference when compared with placebo in two late-stage phase III studies.

                                      5 Health Care ETFs Outperforming XLV on YTD Basis

                                      Health care ETFs provide handsome returns year to date.

                                        Why Ligand (LGND) Could Be an Impressive Growth Stock

                                        If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Ligand (LGND).

                                          Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema

                                          Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same.

                                            Alexion's BLA for ALXN1210 Gets Priority Review From FDA

                                            The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                                              Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

                                              The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.

                                                Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB

                                                Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB

                                                  Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?

                                                  Is (LGND) Outperforming Other Medical Stocks This Year?